Currently receiving an antiretroviral regimen of DTG + ABC/3TC, or ABC/DTG/3TC FDC for ≥ 3 months prior to the screening visit.
HIV ribonucleic acid (RNA) \< 50 copies/mL at the screening visit.
Currently on a stable regimen for ≥ 3 months preceding the screening visit with documented plasma HIV-1 RNA \< 50 copies/mL for ≥ 3 months preceding the screening visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
Have no documented or suspected resistance to emtricitabine (FTC), tenofovir (TFV), DTG, ABC or 3TC.
You may not be if
Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance.
Active tuberculosis infection.
Individuals experiencing decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding).
Females who are pregnant.
Females who are breastfeeding.
Acute hepatitis in the 30 days prior to study entry.
Chronic Hepatitis B Virus (HBV) infection.
Clareo Health | Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed
